Scienture Holdings shares surge 11.81% intraday following FDA-approved REZENOPY® naloxone nasal spray launch and U.S. commercialization plans.

Scienture Holdings surged 11.81% in intraday trading following the announcement of its high-strength REZENOPY® naloxone HCl nasal spray's commercial launch. The FDA-approved product, developed under an exclusive agreement with Summit Biosciences, is set for wholesale distribution in Q1 2026 and market availability by early Q2 2026. This expansion into opioid overdose treatments underscores the company’s strategic focus on addressing a critical U.S. healthcare need, positioning REZENOPY as a high-potential therapeutic option in a growing market. The news directly aligns with the stock’s upward movement, reflecting investor optimism over the product’s commercial viability and market impact.